These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 16857820

  • 1. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA, Johnson BE.
    Clin Cancer Res; 2006 Jul 15; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
    Bonomi PD, Buckingham L, Coon J.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
    [Abstract] [Full Text] [Related]

  • 4. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
    Roengvoraphoj M, Tsongalis GJ, Dragnev KH, Rigas JR.
    Cancer Treat Rev; 2013 Dec 01; 39(8):839-50. PubMed ID: 23768755
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism.
    Nie Q, Yang XN, An SJ, Zhang XC, Yang JJ, Zhong WZ, Liao RQ, Chen ZH, Su J, Xie Z, Wu YL.
    Eur J Cancer; 2011 Sep 01; 47(13):1962-70. PubMed ID: 21616658
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.
    Pesek M, Benesova L, Belsanova B, Mukensnabl P, Bruha F, Minarik M.
    Anticancer Res; 2009 Jul 01; 29(7):2767-73. PubMed ID: 19596959
    [Abstract] [Full Text] [Related]

  • 12. Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors.
    Thomas RK, Greulich H, Yuza Y, Lee JC, Tengs T, Feng W, Chen TH, Nickerson E, Simons J, Egholm M, Rothberg JM, Sellers WR, Meyerson ML.
    Cold Spring Harb Symp Quant Biol; 2005 Jul 01; 70():73-81. PubMed ID: 16869740
    [Abstract] [Full Text] [Related]

  • 13. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T, Liu G, Tsao MS.
    Oncogene; 2009 Aug 01; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [Abstract] [Full Text] [Related]

  • 14. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?
    Dziadziuszko R, Hirsch FR, Varella-Garcia M, Bunn PA.
    Clin Cancer Res; 2006 Jul 15; 12(14 Pt 2):4409s-4415s. PubMed ID: 16857819
    [Abstract] [Full Text] [Related]

  • 15. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
    Wong KK.
    Lung Cancer; 2008 Jun 15; 60 Suppl 2():S10-8. PubMed ID: 18513579
    [Abstract] [Full Text] [Related]

  • 16. Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors.
    Toschi L, Cappuzzo F.
    Oncologist; 2007 Feb 15; 12(2):211-20. PubMed ID: 17296817
    [Abstract] [Full Text] [Related]

  • 17. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
    Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R.
    Clin Cancer Res; 2006 Jul 15; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
    Yi HG, Kim HJ, Kim YJ, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Kim CS, Heo DS, Bang YJ.
    Lung Cancer; 2009 Jul 15; 65(1):80-4. PubMed ID: 19059670
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.